eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2013
vol. 17
 
Share:
Share:
abstract:
Educational article

Transurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated radiotherapy – concomitant boost, with or without concurrent cisplatin, for patients with invasive bladder cancer – clinical outcome

Jadwiga Nowak-Sadzikowska
,
Jerzy Jakubowicz
,
Tomasz Skóra
,
Katarzyna Pudełek

Wspolczesna Onkol 2013; 17 (3): 302–306
Online publish date: 2013/06/28
View full text Get citation
 
PlumX metrics:
Aim of the study: To evaluate the toxicity, clinical effectiveness and survival rate of transurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated radiotherapy (conco­mitant boost), with or without concurrent cisplatin in patients with muscle in­vasive bladder cancer.

Material and methods: Between March 2004 and December 2009, 35 patients with histologically proven invasive carcinoma of the bladder (T2-4a, N0-1, M0), who were fit for combined radioche­mot­herapy and refused radical surgery or were medically or surgically inoperable, were selected for the bladder-sparing protocol.

Results: In this study, twenty-five patients (25/35; 72%) received two cycles of neo­adjuvant chemotherapy, and ten of them (10/35; 28%) only one, because of treatment-related toxicity. In twenty-one pa­tients (21/35; 60%) chemotherapy con­sisting of gemcitabine with cisplatin and in fourteen patients (14/35; 40%) gemcitabine with carboplatin were applied. Only 13 patients (13/35; 37%) received combined irradiation with cisplatin. All patients completed their plan­ned course of radiation therapy. Com­plete response (CR) occurred in 26/35 (74%) patients, partial response (PR) in 2/35(6%), and stable disease (SD) in 7/35 (20%). The overall actuarial survival rates at 3 and 5 years were 75% and 66%, respectively. Disease-specific actuarial survival ra­tes at 3 and 5 years were 81% and 71%, respectively.

Conclusions: Conservative treatment of patients with muscle-invasive bladder cancer by transurethral resection, neoadjuvant chemotherapy, and accelerated hyperfractionated radiotherapy with concomitant boost, with or without concurrent cisplatin, provides a high pro­bability of local and distal response with acceptable toxicity in properly se­lected patients.
keywords:

bladder cancer, transurethral resection, chemotherapy, radiotherapy

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.